Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.
Learn how to recognize adaptive eating behaviors in patients with EoE and why it is important for assessment and management.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE

Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.

Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.
Drs Gutiérrez Junquera and Tzivinikos discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes.

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.
This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.